Health Care Provider Letter
IMPORTANT PRESCRIBING INFORMATION
October 30, 2017
Subject: Temporary importation of Glycophos to address drug shortage issues
Dear Healthcare Professional,
Due to the critical shortage of phosphate injection in the U.S. market, Fresenius Kabi USA, LLC (Fresenius Kabi USA) is coordinating with the U.S. Food and Drug Administration (FDA) to provide an alternative treatment option during this critical shortage period. Fresenius Kabi USA has initiated temporary importation of a GlycophosTM 20 mL Injection Single Dose Plastic Vial into the U.S. market. This product is marketed in Europe, and is manufactured in the Fresenius Kabi Norway plant.
At this time, no other entity except Fresenius Kabi USA is authorized by the FDA to import or distribute GlycophosTM 20 mL Injection Single Dose Plastic Vial in the U.S. FDA has not approved Fresenius Kabi's GlycophosTM in the United States.
Effective immediately, and during this temporary period, Fresenius Kabi USA will offer the following presentation of phosphate injection:
Glycophos 20 mL Sterile Concentrate Single Dose Plastic Vial | |
| Chemical Name | Sodium Glycerophosphate |
| Phosphate Concentration | 1 mMol per mL. |
| Type of Phosphate | Organic |
| Sodium | 2 mEq per mL. |
| Fill Volume | 20 mL. |
| Description | Single Dose Plastic Vial |
| Manufacturer | Fresenius Kabi Norge A/S |
The vial and carton labels will display the text used when marketing the product in English speaking countries.
It is important to note that there are some key differences in the formulation and labeling
between the current U.S. marketed phosphate injection products and Glycophos that you need to be aware of:
Refer to the Glycophos package insert for full prescribing information
This communication and product information is available on the Fresenius Kabi USA web site http://products.fresenius-kabi.us/product-323.html as well as on the FDA Drug Shortage web site. http://www.fda.gov/Drugs/DrugSafety/DrugShortages/default.htm.
To report adverse events or quality problems experienced with the use of this product, call Fresenius Kabi USA Vigilance or Medical Affairs at 1-800-551-7176, Monday – Friday, between the hours of 8 a.m. and 5 p.m. (CST), or e-mail [email protected] or [email protected].
Fresenius Kabi USA CONTACT NUMBERS: Please use the following contact numbers as appropriate:
| Reason To Call | Department | Number |
| ADE Reporting | Vigilance Department | 1-800-551-7176 |
| Clinical/Technical Info. Or Product Complaint | Medical Affairs Department | |
| Product Availability & Ordering | Customer Service Department | 1-888-386-1300 |
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/medwatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 (1-800-332-0178).
- At higher concentrations, solutions of calcium and phosphate may
exist together without precipitating into an insoluble salt complex. - In high pH solutions (admixtures above pH 6.0), organic
phosphate is less likely to precipitate.
Sincerely,
Melanie Power-Burns
Vice President, Quality and Compliance
Key Differences between U.S. Marketed Phosphate Injection Products and Glycophos
| Current U.S. Marketed Inorganic Phosphate Injection, USP | Glycophos | What does this mean to you, as a Healthcare Professional? |
| Indications and contraindications: see package insert | Indications and contraindications: see package insert | Glycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate. Glycophos is contraindicated in patients in a state of dehydration or with hypernatremia, hyperphosphatemia, severe renal insufficiency or shock. |
| Sodium Phosphates and Potassium Phosphates contain 3 mMol of phosphate per mL. | Glycophos contains 1 mMol of phosphate per mL. | Glycophos contains 20 mLs in each plastic vial for a total concentration of 20 mMols of phosphate per vial. Glycophos must be diluted before administration. |
| Sodium Phosphates and Potassium Phosphates are INORGANIC PHOSPHATE. | Glycophos is an ORGANIC PHOSPHATE. | Organic phosphates tend to be more calcium compatible1. This means: |
| Barcode on container label | No unit of use barcode | Any barcodes on Glycophos product will not be appropriately recognized by scanning systems used in the United States and should NOT be used. Institutions should manually input the product into their systems and to confirm that barcode systems do not provide incorrect information when the product is scanned. |
| For questions regarding Glycophos in the United States, please contact Fresenius Kabi USA Medical Affairs at 1-800-551-7176 Option 4, Monday – Friday, between the hours of 8 a.m. and 5 p.m. (CST), or e-mail [email protected]. | ||
1. Data on file.
Comparison Table of U.S. Phosphate Injection Products to Glycophos
| Product Name | Potassium Phosphates | Sodium Phosphates | Glycophos |
| Chemical Name | Potassium Phosphate | Sodium Phosphate | Sodium Glycerophosphate |
| Phosphate Concentration | 3 mMol per mL | 3 mMol per mL | 1 mMol per mL |
| Type of Phosphate | Inorganic | Inorganic | Organic |
| Sodium | Does not contain | 4 mEq per mL | 2 mEq per mL |
| Potassium | 4.4 mEq per mL | Does not contain | Does not contain |
| Fill Volume | 5 mL, 15 mL, 50 mL | 5 mL, 15 mL, 50 mL | 20 mL |
| Description | Single Dose Vial | Single Dose Vial | Single Dose Plastic Vial |
| Companies | Fresenius Kabi USA, Pfizer | American Regent, Fresenius Kabi USA, Pfizer | Fresenius Kabi Norge A/S |
Phosphate Label Product Comparison Table